<DOC>
	<DOCNO>NCT01005095</DOCNO>
	<brief_summary>The investigator hypothesize vitamin D supplementation may ameliorate interferon beta-induced flu-like symptom , owe reduced release activity cytokine correlation adverse event . Vitamin D supplementation may also positively affect injection site reaction due immunomodulatory effect . Vitamin D may also augment therapeutic efficacy interferon beta among multiple sclerosis ( MS ) patient . Vitamin D intake may influence melatonin level MS patient share nuclear receptor .</brief_summary>
	<brief_title>The Effects Interferon Beta Combined With Vitamin D Relapsing Remitting Multiple Sclerosis Patients</brief_title>
	<detailed_description>Detailed Description Study Evaluations Adherence treatment evaluation : Patients ask bring empty package IFN beta Vitamin D use study . Flu like symptom Injection site reaction evaluation : Data regard FLS ISRs collect mean telephone interview every week . The extent FLS day injection evaluate use self-rating scale . A score 0 ( ) 5 ( strong ) , give FLS component , i.e . : myalgia , chill , headache , malaise fatigue , exacerbation neurologic symptom , sweat difficulty function compare time injection . Patient also record oral temperature upon awaken well discretion . All patient provide thermometer . Participants ask report frequency Ibuprofen Paracetamol use . recommend exceed 800mg Ibuprofen 1000mg Paracetamol per day , unless symptom unbearable . Patients inquire subjective degree injection site pain first injection every week , mean 100 mm visual analogue scale ( VAS scale ) . Patients see clinic 3 month interval visit injection site inspect evaluate physician/ nurse grade 0 3 scale : 0-none , 1- pain , itch erythema , 2- swell inflammation 3- ulceration and/or necrosis . Mode application ( manual automatic injection ) well needle size also record . Patients instruct refrain reporting FLS ISRs occasion inter-current febrile illness 4 week corticosteroids treatment . In case , patient postpone report week . MS clinical parameter : Patients clinically evaluate enrollment 6 12 month disease progression , mean EDSS score . The evaluate neurologist blind patient 's treatment . Relapses , characterize emergence new symptom worsen exist one 24 hour absence fever infection ( McDonald et al. , 2001 ) severe enough warrant corticosteroid treatment record . Health related quality life also evaluate baseline completion study , mean MS-specific validate questionnaire - FAMS ( Functional Assessment MS ) ( Miller A , 2006 ) . ( Attached ) Laboratory evaluation : The follow measurement obtain begin study purpose exclude patient baseline impairment mineral metabolism end study evaluate result change mineral homeostasis consequent vitamin D supplementation : blood level 25-OH- vitamin D , PTH , Magnesium , Calcium , Albumin , Creatinine , Urea , Phosphor , Alkaline phosphatase 1-25- di-OH-D . The following measurement assess 3 , 6 12 month study start purpose 25-OH-D level monitoring safety : Calcium , Phosphor , 25-OH-D , Albumin creatinine . Laboratory evaluation require IFN-beta safety include : Complete blood count baseline 3 , 6 , 12 month study start ; liver function test baseline every 3 month , thyroid function test baseline , 6 month end study upon emergence symptom suggestive thyroid dysfunction . Immunological marker : Two venous blood sample draw number participant Baseline 3 month vitamin D supplementation . The first morning IFN beta injection day second morning day injection . The percent rise IFN beta injection IL-6 TRAIL assess commercial ELISA kit . On visit baseline , 3 12 month , venous blood portion store -80 oC within 30 min- 4 hour blood withdrawal MS related cytokine proteins evaluation . On visit baseline 6 month another portion collect immediately immune cell subset evaluation . PBMCs isolate within 4 hour Ficoll gradient centrifugation , stain specific antibody characterize various immune cell subset , subset proportion determine flow cytometry analysis . Blood sample postponed case know condition may possibly influence expression study cytokine . Namely , suspicion new ongoing relapse within 30 day date blood sampling ; Clinical paraclinical sign acute infectious disease 48 hr prior blood sampling ( leukocyte count &gt; 10,000/mcl /or CRP &gt; 2 mg/dl ) ; Clinical sign allergy within 7 day participation ; corticosteroid within 30 day participation . Melatonin : Urine collect 12-hour nighttime ( 20:00-08:00 ) baseline , 3 month end study . Levels melatonin metabolite ( 6-sulphatoxy-melatonin ) assess use highly specific ELISA assay .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Male female patient diagnosis RRMS accord McDonald criterion ( 2005 ) At least 18 year age Patients treat IFNbeta RRMS . The decision treat IFN beta independent study protocol . Patients either newly diagnose , go start IFN beta therapy first time RRMS patient suffer FLS treat IFN beta . Insufficient blood level 25hydroxyvitamin D ( 75nmol/l accord current definition . EDSS score 7 Willing able give inform consent Patients abnormalities vitamin D relate hormonal system low dietary intake decrease sun exposure exclude . Namely , malabsorption [ Celiac , Whipple , Inflammatory bowl disease , Intestinal bypass surgery , Short bowel syndrome , Cirrhosis , Nephrotic syndrome , Hyperthyroidism , Renal failure [ creatinine clearance le 40 ml/min ] , Rickets , Hypoparathyroidism , Hypercalcemia baseline , know malignancy , granulomatous disorder ( Sarcoidosis , Tuberculosis , Silicosis ) Lymphomas . Patients take medication influence vitamin D metabolism , corticosteroid , also exclude . Namely , Orlistat , Anticonvulsants [ Phenobarbital , Primidone , Phenytoin ] , Rifampin , Isoniazide , ketoconazole , 5FU Leucovorin Patients condition increase susceptibility hypercalcemia exclude : know arrhythmia heart disease , treatment Digitalis , Hydrochlorothiazide.and suffer nephrolithiasis . Other Central Nervous System disorder RRMS Psychiatric disorder psychosis , bipolar disorder substance abuse Pregnancy Contraindication treatment IFNbeta</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>